TY - JOUR
T1 - A Southeast Asia Consensus on the Definition and Management of Treatment-Resistant Depression
AU - Tor, Phern Chern
AU - Amir, Nurmiati
AU - Fam, Johnson
AU - Ho, Roger
AU - Ittasakul, Pichai
AU - Maramis, Margarita M.
AU - Ponio, Benita
AU - Purnama, Dharmawan Ardi
AU - Rattanasumawong, Wanida
AU - Rondain, Elizabeth
AU - Sulaiman, Ahmad Hatim Bin
AU - Wiroteurairuang, Kannokarn
AU - Chee, Kok Yoon
N1 - Publisher Copyright:
© 2022 Tor et al.
PY - 2022
Y1 - 2022
N2 - Introduction: Despite the abundance of literature on treatment-resistant depression (TRD), there is no universally accepted definition of TRD and available treatment pathways for the management of TRD vary across the Southeast Asia (SEA) region, highlighting the need for a uniform definition and treatment principles to optimize the management TRD in SEA. Methods: Following a thematic literature review and pre-meeting survey, a SEA expert panel comprising 13 psychiatrists with clinical experience in managing patients with TRD convened and utilized the RAND/UCLA Appropriateness Method to develop consensus-based recommendations on the appropriate definition of TRD and principles for its management. Results: The expert panel agreed that “pharmacotherapy-resistant depression” (PRD) is a more suitable term for TRD and defined it as “failure of two drug treatments of adequate doses, for 4–8 weeks duration with adequate adherence, during a major depressive episode”. A stepwise treatment approach should be employed for the management of PRD – treatment strategies can include maximizing dose, switching to a different class, and augmenting or combining treatments. Non-pharmacological treatments, such as electroconvulsive therapy and repetitive transcranial magnetic stimulation, are also appropriate options for patients with PRD. Conclusion: These consensus recommendations on the operational definition of PRD and treatment principles for its management can be adapted to local contexts in the SEA countries but should not replace clinical judgement. Individual circumstances and benefit-risk balance should be carefully considered while determining the most appropriate treatment option for patients with PRD.
AB - Introduction: Despite the abundance of literature on treatment-resistant depression (TRD), there is no universally accepted definition of TRD and available treatment pathways for the management of TRD vary across the Southeast Asia (SEA) region, highlighting the need for a uniform definition and treatment principles to optimize the management TRD in SEA. Methods: Following a thematic literature review and pre-meeting survey, a SEA expert panel comprising 13 psychiatrists with clinical experience in managing patients with TRD convened and utilized the RAND/UCLA Appropriateness Method to develop consensus-based recommendations on the appropriate definition of TRD and principles for its management. Results: The expert panel agreed that “pharmacotherapy-resistant depression” (PRD) is a more suitable term for TRD and defined it as “failure of two drug treatments of adequate doses, for 4–8 weeks duration with adequate adherence, during a major depressive episode”. A stepwise treatment approach should be employed for the management of PRD – treatment strategies can include maximizing dose, switching to a different class, and augmenting or combining treatments. Non-pharmacological treatments, such as electroconvulsive therapy and repetitive transcranial magnetic stimulation, are also appropriate options for patients with PRD. Conclusion: These consensus recommendations on the operational definition of PRD and treatment principles for its management can be adapted to local contexts in the SEA countries but should not replace clinical judgement. Individual circumstances and benefit-risk balance should be carefully considered while determining the most appropriate treatment option for patients with PRD.
KW - anti-depressive agents
KW - depression
KW - depressive disorder – treatment resistant
KW - major depressive disorder
KW - pharmacotherapy
UR - http://www.scopus.com/inward/record.url?scp=85142265099&partnerID=8YFLogxK
U2 - 10.2147/NDT.S380792
DO - 10.2147/NDT.S380792
M3 - Article
AN - SCOPUS:85142265099
SN - 1176-6328
VL - 18
SP - 2747
EP - 2757
JO - Neuropsychiatric Disease and Treatment
JF - Neuropsychiatric Disease and Treatment
ER -